A new report argues that more flexible eligibility criteria could widen pharma’s clinical trial pool without sacrificing ...

A revamped regulatory framework may give investors less of a “guessing game” as they weigh chances for drug approvals, one ...

Merck is the most exposed to risk from generic competition in the short term, but AbbVie, Johnson & Johnson, Sanofi and ...

Drugmakers are pouring billions into U.S. production, but building enough plants won’t matter without enough skilled workers ...

Ai3Bio recently emerged from stealth with preclinical programs aimed at what it believes could be a root cause of autoimmune ...

Alveus, Lilly, Viking and Amgen are testing maintenance strategies as durability becomes a bigger focus in obesity R&D.

CEOs can make or break a company. And new leaders at three of pharma’s largest drugmakers are taking over with little room for error. All three leaders took the ...

Dr. John Tsai grabbed the reins of global R&D this year with a clear mandate: extend Daiichi’s oncology momentum beyond its ...

As patent protection for the cancer juggernaut Keytruda approaches a critical juncture, Merck & Co. won’t give up market share without a fight. The company revealed this week that a subcutaneous ...

The fundamentals of leadership haven’t changed much in the more than three decades Dr. Mikael Dolsten has been a prominent figure in the pharma industry, most recently as chief scientific officer and ...